YAŞLILIKTA ENDOKRİNOLOJİK HASTALIKLARIN TEDAVİ KILAVUZU Kaynaklar
1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 european
countries, canada, and the united states. JAMA 2003;289:2363-2369.
2. Onat A, Türkmen S, Karabulut A, Yazıcı M, Can G, Sansoy V. Türk Yetişkinlerinde Hiperkolesterolemi ve Hiper-
tansiyon Birlikteliği: Sıklığına ve Kardiyovasküler Riski Öngördümesine İlişkin TEKHARF Çalışması Verileri. Türk
Kardiyoloji Derneği Arşivi 2004; 32:533-54.
3. Aronow WS, Sales FF, Etienne F, Lee NH. Prevalence of peripheral arterial disease and its correlation with risk fac-
tors for peripheral arterial disease in elderly patients in a long-term health care facility. Am J Cardiol 1988;62:644-
646.
4. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart di-
sease. Overall fi ndings and differences by age for 316,099 white men. Multiple risk factor interventiontrial research
group. Arch Intern Med 1992;152:56-64.
5. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older.
6. Black HR, Kuller LH, O’Rourke MF, et al. The first report of the systolic and pulse pressure (sypp) working group.
J Hypertens Suppl 1999;17:S3-14.
7. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change
with aging? The Framingham Heart Study. Circulation 2001; 103:1245.
8. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United Sta-
tes, 1988 to 2008. Circulation 2011; 124:1046.
9. http ://www.uptodate.com/contents/ Treatment of hypertension in the elderly patient, particularly isolated systolic
hypertension
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with
isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA.
1991;265:3255–3264
11. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Practice guidelines for the management of arterial hypertension of
the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force
for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925-1938
12. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in
adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;
DOI:10.1001/jama.2013.284427.
13. Leung AA, Nerenberg K, Daskalopoulou SS et al. Hypertension Canada’s 2016 Canadian Hypertension Education
Program Guidelines for Blood Pressure, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.
CHEP Guidelines Task Force. Can J Cardiol. 2016 May;32(5):569-88. doi: 10.1016/j.cjca.2016.02.066.
14. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the
community. A statement by the American Society of Hypertension and the International Society of Hypertension.
J Hypertens 2014; 32:3-15.
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events
in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967–1975.
16. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in
high-risk patients. N Engl J Med 2008; 359:2417.
17. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascu-
lar Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA 2016; 315:2673.
18. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive
patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884.